<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610710</url>
  </required_header>
  <id_info>
    <org_study_id>Horsens MR</org_study_id>
    <nct_id>NCT04610710</nct_id>
  </id_info>
  <brief_title>Impact of Operation on Fertility for Women With Severe Endometriosis</brief_title>
  <acronym>EFFORT</acronym>
  <official_title>Comparing Impact of Operation and Fertility Treatment on Fertility for Women With Deep Infiltrating Endometriosis: A Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horsens Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Tivoli Ducos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Horsens Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The EFFORT study compares the impact on fertility of operation or fertility treatment (IVF,&#xD;
      in vitro fertilization) in a multicenter randomized controlled trial. The study population&#xD;
      consists of women with colorectal deep infiltrating endometriosis and a pregnancy intention.&#xD;
      These women will be randomized to either of the two treatment groups: Group A = Operation or&#xD;
      Group B = fertility treatment (IVF). Group A will be further divided postoperatively into&#xD;
      spontaneous conception or IVF depending on the Endometriosis Fertility Index score.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Clinical Trail (RCT)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative pregnancy rate</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of cumulative pregnancies defined as viable pregnancies at gestational age 6-8 within the 18 months´ follow-up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Live birth rate (LBR)</measure>
    <time_frame>18 months</time_frame>
    <description>Rate live births</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-viable pregnancies</measure>
    <time_frame>18 months</time_frame>
    <description>Number biochemical pregnancies, pregnancies of unknown location (PUL), extrauterine pregnancies, miscarriages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian potential</measure>
    <time_frame>Baseline, 9 -18 month</time_frame>
    <description>Concentration of Anti-Müllerian hormone (AMH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pregnancy</measure>
    <time_frame>18 months</time_frame>
    <description>Shortest time from intervention to the first ongoing pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative complications</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of complications in accordance to Clavien-Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertility treatment complications</measure>
    <time_frame>18 months</time_frame>
    <description>Rate of hospital admissions, superinfection, worsening of pain or having ovarian hyperstimulation syndrome (OHSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>Baseline, 9 and 18 months</time_frame>
    <description>Visual analog score (VAS) from 1 to 10, where 10 implies the worst pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline, 9 and 18 months</time_frame>
    <description>Development in Endometriosis health profile (EHP-30+23)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel function</measure>
    <time_frame>Baseline, 9 and 18 months</time_frame>
    <description>Development in bowel function rated by Low anterior resection syndrome (LARS) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary tract function</measure>
    <time_frame>Baseline, 9 and 18 months</time_frame>
    <description>Development in urinary tract function rated by International Consultation on Incontinence Questionnaire (ICIQ- FLUTS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometriosis inflammatory status</measure>
    <time_frame>Baseline and 18 months</time_frame>
    <description>Concentrations of inflammatory markers in blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Deep Endometriosis</condition>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Operation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Operation for severe endometriosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fertility treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fertility treatment for women with severe endometriosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Operation</intervention_name>
    <description>Operation for deep infiltrating endometriosis</description>
    <arm_group_label>Operation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fertility treatment</intervention_name>
    <description>In vitro fertilisation (IVF) and IVF-intracytoplasmic injection (ICSI)</description>
    <arm_group_label>Fertility treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rectosigmoid endometriosis and wish for surgery&#xD;
&#xD;
          -  Pregnancy intention for at least 6 months&#xD;
&#xD;
          -  AMH above 5 pmol/ml&#xD;
&#xD;
          -  Maximum of 2 previous IVF treatments&#xD;
&#xD;
          -  Male partner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Endometriosis involving the ureter unilaterally or bilaterally (randomization&#xD;
             unethical)&#xD;
&#xD;
          -  BMI above 32&#xD;
&#xD;
          -  Contraindication for IVF (untreated uterine factor infertility, untreated/maltreated&#xD;
             systemic or malignant disease, oocyte aspiration severely riskful (e.g. severe&#xD;
             abdominal adhesions)&#xD;
&#xD;
          -  No wish for randomization&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ulla B Knudsen, Professor</last_name>
    <phone>+45 78426592</phone>
    <email>ubk@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maja Raos</last_name>
    <email>majaraos@clin.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <state>Central Region</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikkel Seyer-Hansen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Horsens Regional Hospital</name>
      <address>
        <city>Horsens</city>
        <state>Central Region</state>
        <zip>8700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulla B Knudsen, Professor</last_name>
      <phone>+45 7842 6592</phone>
      <email>ubk@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Endometriosis Center, Clinique Tivoli-Ducos</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Horace Roman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Horsens Hospital</investigator_affiliation>
    <investigator_full_name>Ulla Breth Knudsen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

